Abstract: The invention relates to a compound comprising non-peptide prokineticin receptors antagonists and agents that modulate or inhibit the activity of prokineticin receptors for use in the treatment of immune-mediated diseases of the central nervous system, peripheral nervous system and neuromuscular junctions.

Abstract: The patent refers to a screening method carried out on biological material isolated from human and/or animal organisms for determining the risk of human and/or animal pathologies expressing an anomalous deposition of ?-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, based on the investigation of the punctiform mutation Ala>Val in position 2 of the ?-protein (corresponding to the Ala673Val mutation precursor of the ?-protein containing 770 amino acids) in homozygosis or in heterozygosis. The patent provides for the possibility of: (1) creating unicellular or multicellular transgenic organisms expressing the Ala673Val mutation; (2) synthesising or producing peptides with such mutation and/or their derivatives and/or nucleic acids containing the same mutation; (3) using such products for studying the pathogenesis of the pathologies characterised by anomalous deposition of ?-amyloid and/or amyloid substance and for the prevention, diagnosis and care of such diseases.

Abstract: Proteins and/or peptides originate from the gene which results from the retention of the intron 3 of the gene SMN identified in the gene bank with the access number AY876898 with use for the diagnosis and/or prevention and/or treatment of neurodegenerative diseases.